Core Viewpoint - The approval of the acetate prednisolone raw material drug by the National Medical Products Administration is expected to enhance the company's product line and competitiveness in the hormone drug market [1] Group 1: Company Developments - The company received the approval notice for the acetate prednisolone chemical raw material drug application from the National Medical Products Administration [1] - The application for this raw material drug was submitted in March 2024 and has been accepted for review [1] - The approval is anticipated to enrich the company's hormone product line [1] Group 2: Market Context - The acetate prednisolone is primarily used for allergic and autoimmune inflammatory diseases [1] - The estimated sales revenue for acetate prednisolone formulations in Chinese public medical institutions is approximately 100 million yuan in 2024 [1] - The sales of the drug may be influenced by industry policies and market conditions, indicating potential uncertainties [1]

智通财经APP讯，新华制药(000756.SZ)公告，公司收到国家药品监督管理局核准签发的盐酸肾上腺素注 射液《药品补充申请批准通知书》，本品通过仿制药质量和疗效一致性评价。本品主要适用于因支气管 痉挛所致严重呼吸困难，可迅速缓解药物等引起的过敏性休克，亦可用于延长浸润麻醉用药的作用时 间，是各种原因引起的心脏骤停进行心肺复苏的主要抢救用药。 ...

Core Viewpoint - Shandong Xinhua Pharmaceutical has received approval from the National Medical Products Administration for the listing of Acetate Prednisolone as a chemical raw material drug, indicating a significant advancement in its product portfolio and potential market opportunities [1] Company Summary - The company submitted the registration application for Acetate Prednisolone to the National Medical Products Administration's CDE in March 2024, which was accepted [1] - The approval notification for the listing was granted in November 2025, with the review conclusion being a registration approval [1] - Acetate Prednisolone is primarily used for allergic and autoimmune inflammatory diseases, including active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, nephrotic syndrome, and others [1] Industry Summary - The sales revenue of Acetate Prednisolone-related formulations in Chinese public medical institutions is estimated to be approximately RMB 100 million in 2024 [1]

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the marketing application of Acetate Prednisolone, indicating a significant advancement in its product portfolio and potential revenue growth in the pharmaceutical market [1] Company Summary - The company submitted the registration application for Acetate Prednisolone to the National Medical Products Administration's CDE in March 2024, which was accepted [1] - The approval notification for the marketing application was granted in November 2025, with the review conclusion being a registration approval [1] Industry Summary - Acetate Prednisolone is primarily used for allergic and autoimmune inflammatory diseases, including active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, nephrotic syndrome, thrombocytopenic purpura, granulocytopenia, various adrenal cortical insufficiencies, severe dermatitis, and acute leukemia, among others [1] - The sales revenue of Acetate Prednisolone-related formulations in Chinese public medical institutions is estimated to be approximately RMB 100 million in 2024 [1]

本品主要适用于因支气管痉挛所致严重呼吸困难，可迅速缓解药物等引起的过敏性休克，亦可用于延长 浸润麻醉用药的作用时间，是各种原因引起的心脏骤停进行心肺复苏的主要抢救用药。 格隆汇11月27日丨山东新华制药股份(00719.HK)公布，近日，公司收到国家药品监督管理局核准签发的 盐酸肾上腺素注射液(以下简称"本品")《药品补充申请批准通知书》，本品通过仿制药质量和疗效一致 性评价。 ...

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the marketing application of Acetate Prednisolone, which is primarily used for allergic and autoimmune inflammatory diseases [1] Group 1: Product Approval - The company has been granted a marketing approval notification for Acetate Prednisolone, indicating a significant regulatory milestone [1] - This product is mainly utilized for various conditions including active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, nephrotic syndrome, thrombocytopenic purpura, neutropenia, adrenal insufficiency, severe dermatitis, and acute leukemia [1] - Acetate Prednisolone is also used in the comprehensive treatment of certain infections, showcasing its versatility in therapeutic applications [1]

Core Viewpoint - The pet economy sector experienced a slight increase of 0.14% on November 26, with Renmin Tongtai leading the gains, while the overall market showed mixed results with the Shanghai Composite Index down by 0.15% and the Shenzhen Component Index up by 1.02% [1] Group 1: Market Performance - The Shanghai Composite Index closed at 3864.18, down 0.15% [1] - The Shenzhen Component Index closed at 12907.83, up 1.02% [1] - The pet economy sector stocks showed varied performance, with Renmin Tongtai rising by 10.02% to a closing price of 13.18 [1] Group 2: Individual Stock Performance - Renmin Tongtai (600829) led the sector with a closing price of 13.18 and a trading volume of 538,900 shares, resulting in a transaction value of 672 million [1] - Aoni Electronics (301189) increased by 6.34% to 40.09, with a transaction value of 332 million [1] - Xinhua Pharmaceutical (000756) rose by 5.77% to 18.15, with a transaction value of 159.5 million [1] Group 3: Capital Flow - The pet economy sector saw a net outflow of 27.86 million from institutional investors and 74.23 million from retail investors, while retail investors had a net inflow of 102 million [2][3] - Renmin Tongtai experienced a net inflow of 115 million from institutional investors, despite a net outflow of 51.93 million from retail investors [3] - Xinhua Pharmaceutical had a net inflow of 68.19 million from institutional investors, with a net outflow of 21.72 million from retail investors [3]

Market Performance - The Shandong state-owned enterprise reform sector rose by 0.45% compared to the previous trading day, with Xinhua Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3864.18, down 0.15%, while the Shenzhen Component Index closed at 12907.83, up 1.02% [1] Stock Highlights - Xinhua Pharmaceutical (000756) closed at 18.15, up 5.77% with a trading volume of 877,900 shares and a transaction value of 1.595 billion [1] - Inspur Information (000977) closed at 63.56, up 5.74% with a trading volume of 995,400 shares and a transaction value of 6.266 billion [1] - Other notable stocks include Jiri Co. (002083) up 3.50%, Shantui Co. (000680) up 3.02%, and Haizhu Co. (301262) up 3.01% [1] Capital Flow - The Shandong state-owned enterprise reform sector saw a net inflow of 885 million in main funds, while retail investors experienced a net outflow of 449 million [2] - The main funds showed significant inflows into stocks like Inspur Information and Xinhua Pharmaceutical, while retail investors withdrew from several stocks [3] Individual Stock Capital Flow - Inspur Information had a main fund net inflow of 11.37 billion, while retail investors saw a net outflow of 6.40 billion [3] - Xinhua Pharmaceutical experienced a main fund net inflow of 68.2 million, with retail investors withdrawing 46.5 million [3] - Other stocks like Shandong Steel (600022) and Qingdao Food (001219) also showed varied capital flows, indicating differing investor sentiments [3]

Core Viewpoint - The chemical pharmaceutical sector experienced a rise of 1.66% on November 26, with Frontier Biotech leading the gains, while the overall Shanghai Composite Index fell by 0.15% [1]. Group 1: Stock Performance - Frontier Biotech (688221) closed at 20.20, up 12.85% with a trading volume of 455,500 shares and a transaction value of 916 million yuan [1]. - Yuyuan Pharmaceutical (688658) closed at 26.88, up 12.00% with a trading volume of 218,600 shares and a transaction value of 577 million yuan [1]. - Fuyuan Pharmaceutical (6801089) closed at 24.53, up 10.00% with a trading volume of 113,800 shares and a transaction value of 274 million yuan [1]. - Other notable performers include Guangji Pharmaceutical (000952) with a 9.99% increase and Beida Pharmaceutical (000788) with a 9.94% increase [1]. Group 2: Fund Flow Analysis - The chemical pharmaceutical sector saw a net inflow of 43.08 million yuan from institutional investors, while retail investors contributed a net inflow of 23.8 million yuan [2]. - The sector experienced a net outflow of 281 million yuan from speculative funds [2]. - Key stocks with significant fund flows include Heng Rui Pharmaceutical (600276) with a net inflow of 231 million yuan from institutional investors [3]. Group 3: Individual Stock Fund Flow - New China Pharmaceutical (000756) had a net inflow of 68.2 million yuan from institutional investors, while experiencing a net outflow of 21.7 million yuan from speculative funds [3]. - Fuyuan Pharmaceutical (601089) saw a net inflow of 67.6 million yuan from institutional investors, with a net outflow of 39.4 million yuan from speculative funds [3]. - Other stocks like Beibete (688759) and Yuyuan Pharmaceutical (688658) also showed varying levels of net inflows and outflows from different investor categories [3].

Group 1 - Runjian Co., Ltd. is planning to issue H-shares and list on the Hong Kong Stock Exchange [1] - Zhongfu Shenying's shareholder plans to reduce its stake by no more than 1% [2] - Chenxi Aviation's controlling shareholder intends to reduce its stake by up to 3% [2] Group 2 - Zhiguang Electric's subsidiary signed a sales contract worth 152 million yuan [3] - Sanrenxing's controlling shareholder and actual controller plan to transfer up to 8% of the company's shares [4] - Guosheng Technology intends to acquire 100% equity of Fuyue Technology for 241 million yuan [5] Group 3 - Luxiao Technology's controlling shareholder plans to reduce its stake by no more than 3% [7] - Fusenmei's vice president and board secretary are under investigation [8] - Zhongchuang Co., Ltd. plans to transfer 2% of its shares through inquiry [10] Group 4 - Anglikang plans to raise 1.16 billion yuan for innovative drug research and industrialization projects [12] - Shenling Environment intends to issue convertible bonds to raise no more than 1 billion yuan [14] - Songcheng Performing Arts plans to acquire 100% equity of Hangzhou Songcheng Industrial for 963 million yuan [16] Group 5 - Demingli plans to raise no more than 3.2 billion yuan for SSD and DRAM expansion projects [17] - Ziyan Food's three shareholders plan to reduce their stake by no more than 276,700 shares [18] - Xinhua Pharmaceutical received a drug registration certificate for a new product [20] Group 6 - Chunqiu Electronics plans to acquire all shares of Danish liquid cooling technology company Asetek A/S for up to 547 million Danish kroner [22] - Tiandi Digital intends to transfer 100% equity of its subsidiary for 49 million yuan [24] - Huaru Technology plans to invest 20 million yuan to establish a fund focusing on new digital technologies [25] Group 7 - *ST Dongtong's stock may be suspended due to regulatory penalties for false reporting [26] - Siryipu is planning to acquire shares of Ningbo Aola Semiconductor and will suspend trading [27] - Purang Co., Ltd. is planning to acquire 49% equity of Noah Changtian and will suspend trading [29] Group 8 - *ST Suwu is facing potential delisting due to significant violations in financial reporting [32]